Do analysts recommend PFSA or HSCS?

HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 164.03%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts clearly believe HeartSciences is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PFSA or HSCS more profitable?

Profusa's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,731.09% HeartSciences N/A -358.60% -144.82%

Do analysts recommend MBAI or PFSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, MBAI or PFSA?

Check-Cap has higher earnings, but lower revenue than Profusa. Check-Cap is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Check-Cap N/A N/A $4.14M -$14.07 N/A Profusa $100K 17.87 -$35.82M -$5.62 thousand N/A

Is MBAI or PFSA more profitable?

Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A Profusa N/A N/A -1,731.09%

Does the media prefer MBAI or PFSA?

In the previous week, Check-Cap had 1 more articles in the media than Profusa. MarketBeat recorded 5 mentions for Check-Cap and 4 mentions for Profusa. Check-Cap's average media sentiment score of 0.72 beat Profusa's score of 0.38 indicating that Check-Cap is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Profusa 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ICCM or PFSA?

IceCure Medical presently has a consensus target price of $52.50, suggesting a potential upside of 2,182.61%. Given IceCure Medical's stronger consensus rating and higher possible upside, equities research analysts plainly believe IceCure Medical is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IceCure Medical 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ICCM or PFSA?

IceCure Medical has higher revenue and earnings than Profusa. IceCure Medical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IceCure Medical $3.38M 2.33 -$15.06M -$8.52 N/A Profusa $100K 17.87 -$35.82M -$5.62 thousand N/A

Is ICCM or PFSA more profitable?

Profusa has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. Profusa's return on equity of 0.00% beat IceCure Medical's return on equity. Company Net Margins Return on Equity Return on Assets IceCure Medical -427.67% -174.26% -112.58% Profusa N/A N/A -1,731.09%

Does the media refer more to ICCM or PFSA?

In the previous week, Profusa had 2 more articles in the media than IceCure Medical. MarketBeat recorded 4 mentions for Profusa and 2 mentions for IceCure Medical. Profusa's average media sentiment score of 0.38 beat IceCure Medical's score of 0.28 indicating that Profusa is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IceCure Medical 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Profusa 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NVNO or PFSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, NVNO or PFSA?

enVVeno Medical has higher earnings, but lower revenue than Profusa. enVVeno Medical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enVVeno Medical N/A N/A -$19.47M -$19.33 N/A Profusa $100K 17.87 -$35.82M -$5.62 thousand N/A

Is NVNO or PFSA more profitable?

Profusa's return on equity of 0.00% beat enVVeno Medical's return on equity. Company Net Margins Return on Equity Return on Assets enVVeno Medical N/A -62.28% -56.83% Profusa N/A N/A -1,731.09%

Does the media prefer NVNO or PFSA?

In the previous week, Profusa had 2 more articles in the media than enVVeno Medical. MarketBeat recorded 4 mentions for Profusa and 2 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 0.47 beat Profusa's score of 0.38 indicating that enVVeno Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enVVeno Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Profusa 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PFSA or NXL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, PFSA or NXL?

Nexalin Technology has higher revenue and earnings than Profusa. Nexalin Technology is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa $100K 17.87 -$35.82M -$5.62 thousand N/A Nexalin Technology $300K 18.72 -$8.22M -$0.48 N/A

Is PFSA or NXL more profitable?

Profusa has a net margin of 0.00% compared to Nexalin Technology's net margin of -4,141.94%. Profusa's return on equity of 0.00% beat Nexalin Technology's return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,731.09% Nexalin Technology -4,141.94% -278.24% -218.42%

Does the media refer more to PFSA or NXL?

In the previous week, Nexalin Technology had 2 more articles in the media than Profusa. MarketBeat recorded 6 mentions for Nexalin Technology and 4 mentions for Profusa. Profusa's average media sentiment score of 0.38 beat Nexalin Technology's score of 0.31 indicating that Profusa is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profusa 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nexalin Technology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Profusa (PFSA) Competitors

$2.93 -1.31 (-30.90%)

As of 08/28/2026 04:00 PM Eastern

Compare

PFSA vs. HSCS, MBAI, ICCM, NVNO, and NXL

Should you buy Profusa stock or one of its competitors? Profusa's main competitors and comparable companies include HeartSciences (HSCS), Check-Cap (MBAI), IceCure Medical (ICCM), enVVeno Medical (NVNO), and Nexalin Technology (NXL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Profusa compare to HeartSciences?

Profusa (NASDAQ:PFSA) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Profusa has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 164.03%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts clearly believe HeartSciences is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has lower revenue, but higher earnings than Profusa. HeartSciences is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	17.87	-$35.82M	-$5.62 thousand	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A

In the previous week, Profusa had 2 more articles in the media than HeartSciences. MarketBeat recorded 4 mentions for Profusa and 2 mentions for HeartSciences. HeartSciences' average media sentiment score of 1.44 beat Profusa's score of 0.38 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Profusa	Neutral
HeartSciences	Positive

Profusa's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,731.09%
HeartSciences	N/A	-358.60%	-144.82%

9.8% of Profusa shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 0.8% of Profusa shares are owned by company insiders. Comparatively, 4.9% of HeartSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

HeartSciences beats Profusa on 10 of the 14 factors compared between the two stocks.

How does Profusa compare to Check-Cap?

Check-Cap (NASDAQ:MBAI) and Profusa (NASDAQ:PFSA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Check-Cap had 1 more articles in the media than Profusa. MarketBeat recorded 5 mentions for Check-Cap and 4 mentions for Profusa. Check-Cap's average media sentiment score of 0.72 beat Profusa's score of 0.38 indicating that Check-Cap is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profusa	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Check-Cap has higher earnings, but lower revenue than Profusa. Check-Cap is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$14.07	N/A
Profusa	$100K	17.87	-$35.82M	-$5.62 thousand	N/A

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Profusa	N/A	N/A	-1,731.09%

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 9.8% of Profusa shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 0.8% of Profusa shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Check-Cap has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Profusa has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Summary

Check-Cap beats Profusa on 6 of the 10 factors compared between the two stocks.

How does Profusa compare to IceCure Medical?

IceCure Medical (NASDAQ:ICCM) and Profusa (NASDAQ:PFSA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

IceCure Medical has higher revenue and earnings than Profusa. IceCure Medical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	2.33	-$15.06M	-$8.52	N/A
Profusa	$100K	17.87	-$35.82M	-$5.62 thousand	N/A

IceCure Medical has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Profusa has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

IceCure Medical presently has a consensus target price of $52.50, suggesting a potential upside of 2,182.61%. Given IceCure Medical's stronger consensus rating and higher possible upside, equities research analysts plainly believe IceCure Medical is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Profusa had 2 more articles in the media than IceCure Medical. MarketBeat recorded 4 mentions for Profusa and 2 mentions for IceCure Medical. Profusa's average media sentiment score of 0.38 beat IceCure Medical's score of 0.28 indicating that Profusa is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Profusa	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 0.8% of Profusa shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profusa has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. Profusa's return on equity of 0.00% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
Profusa	N/A	N/A	-1,731.09%

Summary

IceCure Medical and Profusa tied by winning 8 of the 16 factors compared between the two stocks.

How does Profusa compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and Profusa (NASDAQ:PFSA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

In the previous week, Profusa had 2 more articles in the media than enVVeno Medical. MarketBeat recorded 4 mentions for Profusa and 2 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 0.47 beat Profusa's score of 0.38 indicating that enVVeno Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enVVeno Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Profusa	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

enVVeno Medical has higher earnings, but lower revenue than Profusa. enVVeno Medical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A
Profusa	$100K	17.87	-$35.82M	-$5.62 thousand	N/A

34.7% of enVVeno Medical shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 15.0% of enVVeno Medical shares are held by insiders. Comparatively, 0.8% of Profusa shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profusa's return on equity of 0.00% beat enVVeno Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-62.28%	-56.83%
Profusa	N/A	N/A	-1,731.09%

enVVeno Medical has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Profusa has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Summary

enVVeno Medical beats Profusa on 9 of the 13 factors compared between the two stocks.

How does Profusa compare to Nexalin Technology?

Profusa (NASDAQ:PFSA) and Nexalin Technology (NASDAQ:NXL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Nexalin Technology has higher revenue and earnings than Profusa. Nexalin Technology is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	17.87	-$35.82M	-$5.62 thousand	N/A
Nexalin Technology	$300K	18.72	-$8.22M	-$0.48	N/A

9.8% of Profusa shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 0.8% of Profusa shares are owned by company insiders. Comparatively, 16.9% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profusa has a net margin of 0.00% compared to Nexalin Technology's net margin of -4,141.94%. Profusa's return on equity of 0.00% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,731.09%
Nexalin Technology	-4,141.94%	-278.24%	-218.42%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Profusa has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, Nexalin Technology has a beta of 4, meaning that its stock price is 300% more volatile than the broader market.

In the previous week, Nexalin Technology had 2 more articles in the media than Profusa. MarketBeat recorded 6 mentions for Nexalin Technology and 4 mentions for Profusa. Profusa's average media sentiment score of 0.38 beat Nexalin Technology's score of 0.31 indicating that Profusa is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profusa	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nexalin Technology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Nexalin Technology beats Profusa on 8 of the 13 factors compared between the two stocks.

Get Profusa News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PFSA vs. The Competition

Export

Metric	Profusa	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.77M	$5.84B	$7.20B	$12.90B
Dividend Yield	N/A	1.75%	2.54%	11.28%
P/E Ratio	0.00	25.92	273.16	25.45
Price / Sales	17.87	67.90	592.64	73.57
Price / Cash	N/A	33.03	76.74	53.00
Price / Book	-0.07	6.18	12.98	6.14
Net Income	-$35.82M	$149.01M	$3.48B	$348.86M
7 Day Performance	-46.34%	-0.24%	0.13%	-0.80%
1 Month Performance	-30.90%	6.18%	7.08%	4.13%
1 Year Performance	N/A	6.30%	24.67%	15.17%

Profusa Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PFSA Profusa	0.7956 of 5 stars	$2.93 -30.9%	N/A	N/A	$1.77M	$100K	N/A	2	Analyst Upgrade Gap Down
HSCS HeartSciences	2.7879 of 5 stars	$2.99 -0.3%	$8.00 +167.6%	-11.1%	$11.70M	N/A	N/A	10	Positive News Short Interest Decrease
MBAI Check-Cap	0.7276 of 5 stars	$6.78 -16.1%	N/A	N/A	$11.11M	N/A	N/A	80	News Coverage Short Interest Decrease High Trading Volume
ICCM IceCure Medical	2.3672 of 5 stars	$2.29 +0.4%	$52.50 +2,192.6%	-93.2%	$7.81M	$3.38M	N/A	60
NVNO enVVeno Medical	1.5225 of 5 stars	$11.47 +6.2%	N/A	-61.6%	$7.50M	N/A	N/A	30	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PFSA) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Profusa (PFSA) Competitors

PFSA vs. HSCS, MBAI, ICCM, NVNO, and NXL

How does Profusa compare to HeartSciences?

Summary

How does Profusa compare to Check-Cap?

Summary

How does Profusa compare to IceCure Medical?

Summary

How does Profusa compare to enVVeno Medical?

Summary

How does Profusa compare to Nexalin Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSA vs. The Competition

Profusa Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Profusa (PFSA) Competitors

PFSA vs. HSCS, MBAI, ICCM, NVNO, and NXL

How does Profusa compare to HeartSciences?

Which has more risk & volatility, PFSA or HSCS?

Do analysts recommend PFSA or HSCS?

Which has preferable earnings and valuation, PFSA or HSCS?

Does the media favor PFSA or HSCS?

Is PFSA or HSCS more profitable?

Do institutionals & insiders hold more shares of PFSA or HSCS?

Summary

How does Profusa compare to Check-Cap?

Do analysts recommend MBAI or PFSA?

Does the media prefer MBAI or PFSA?

Which has higher valuation & earnings, MBAI or PFSA?

Is MBAI or PFSA more profitable?

Do insiders and institutionals believe in MBAI or PFSA?

Which has more risk and volatility, MBAI or PFSA?

Summary

How does Profusa compare to IceCure Medical?

Which has preferable earnings and valuation, ICCM or PFSA?

Which has more risk and volatility, ICCM or PFSA?

Do analysts rate ICCM or PFSA?

Does the media refer more to ICCM or PFSA?

Do insiders & institutionals have more ownership in ICCM or PFSA?

Is ICCM or PFSA more profitable?

Summary

How does Profusa compare to enVVeno Medical?

Does the media prefer NVNO or PFSA?

Do analysts prefer NVNO or PFSA?

Which has better earnings & valuation, NVNO or PFSA?

Do institutionals and insiders hold more shares of NVNO or PFSA?

Is NVNO or PFSA more profitable?

Which has more risk & volatility, NVNO or PFSA?

Summary

How does Profusa compare to Nexalin Technology?

Which has stronger valuation & earnings, PFSA or NXL?

Do institutionals & insiders hold more shares of PFSA or NXL?

Is PFSA or NXL more profitable?

Do analysts prefer PFSA or NXL?

Which has more risk and volatility, PFSA or NXL?

Does the media refer more to PFSA or NXL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSA vs. The Competition

Profusa Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools